Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

11.09 +0.18 (+1.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,226,403
Open 11.03
Bid (Size) 10.73 (1)
Ask (Size) 11.25 (1)
Prev. Close 10.91
Today's Range 11.00 - 11.21
52wk Range 5.910 - 13.84
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for Amicus Therapeutics
 
Via Benzinga
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
-7.04%
-7.04%
1 Month
-18.09%
-18.09%
3 Month
-9.17%
-9.17%
6 Month
+6.23%
+6.23%
1 Year
+17.11%
+17.11%

More News

Read More
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Earnings Scheduled For March 1, 2023
Via Benzinga
Earnings Preview: Amicus Therapeutics
Via Benzinga
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy
Via Benzinga
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
Via Benzinga
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Recap: Amicus Therapeutics Q3 Earnings
Via Benzinga
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Announces Participation at World Muscle Society 2022
From Amicus Therapeutics, Inc.
Via Globe NewsWire
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.